US Supreme Court Temporarily Lifts Ban on Abortion Pill Mail Delivery

The United States Supreme Court has temporarily lifted a ban on the mail delivery of the abortion pill mifepristone, restoring telehealth access to the medication while legal challenges continue.

Legal Background

In 2023, the Food and Drug Administration (FDA) implemented a rule allowing mifepristone to be prescribed via telemedicine and dispensed through the mail. The state of Louisiana challenged this rule, leading to a ruling by the Fifth Circuit Court of Appeals that reinstated the requirement for in-person consultations to obtain the drug.

Supreme Court's Intervention

On May 4, 2026, Justice Samuel Alito issued an order temporarily pausing the Fifth Circuit's ruling, thereby allowing the continued distribution of mifepristone through telehealth services and mail delivery. This administrative stay is set to expire on May 11, 2026, providing the Court time to consider the case further.

Implications for Abortion Access

Mifepristone, used in combination with misoprostol, is a widely used method for medication abortions in the United States. The Supreme Court's temporary order maintains access to this method without the need for in-person visits, which is particularly significant in states with restrictive abortion laws.

For more detailed information, refer to the original article on Al Jazeera: US Supreme Court Temporarily Lifts Ban on Abortion Pill Mail Delivery.